Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Bio Green Med Solution, Inc. Director's Dealing 2023

Dec 26, 2023

35092_dirs_2023-12-26_6882a32b-e56f-415f-aa67-5b76bb40e0a3.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Cyclacel Pharmaceuticals, Inc. (CYCC)
CIK: 0001130166
Period of Report: 2023-12-21

Reporting Person: McBarron Paul (Director, See Remarks)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2023-12-21 Common Stock P 1886 $3.315 Acquired 33378 Direct

Derivative Transactions

Date Security Exercise Price Code Shares A/D Expiration Underlying Ownership
2023-12-21 Warrants (right to buy) $3.19 P 1886 Acquired 2030-12-21 Common Stock (1886) Direct

Footnotes

F1: The Reporting Person purchased unregistered shares of the Issuer's common stock in a private placement, pursuant to a Securities Purchase Agreement between the Reporting Person and the Issuer.

F2: Each share of common stock was purchased with an accompanying warrant at an aggregate purchase price of $3.315 per share and accompanying warrant.